Breakthrough Blood Test Predicts Dementia Risk 25 Years Before Symptoms

Scientists have unveiled a groundbreaking blood test that could predict a woman's risk of developing dementia up to 25 years before symptoms appear. The discovery, published in the journal JAMA Network Open, marks a potential shift in how dementia is diagnosed and managed. Researchers identified a protein, p-tau217, in blood samples that is strongly linked to the brain changes characteristic of Alzheimer's disease. This protein is associated with the formation of amyloid plaques and neurofibrillary tangles, the hallmark deposits that damage brain cells and disrupt communication.

The study followed 2,766 women aged 65 to 79 participating in the Women's Health Initiative Memory Study. All participants were cognitively healthy at the start of the research. Over a 25-year period, researchers tracked the development of mild cognitive impairment and dementia. Women with higher levels of p-tau217 in their blood were found to be three times more likely to develop dementia later in life. The findings suggest that this biomarker could enable earlier identification of at-risk individuals, allowing for targeted monitoring and intervention strategies.

Professor Aladdin Shadyab, lead author of the study from the University of California San Diego, emphasized the significance of the lead time. 'That kind of long lead time opens the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life,' he said. This approach could transform current diagnostic methods, which typically rely on noticeable symptoms after the disease has already progressed.

The study also revealed that risk factors varied across different groups. Women aged 70 or older at the start of the study who had high levels of p-tau217 showed stronger signs of cognitive decline than younger participants. The protein was more strongly linked to poor cognitive outcomes in women carrying the APOE-E4 gene, a known risk factor for Alzheimer's. Additionally, women on hormone replacement therapy (HRT) who also had high levels of p-tau217 were more likely to develop dementia.

Menopause has been previously linked to reductions in brain grey matter, which contains most of the brain's nerve cells and plays a critical role in memory, emotions, and movement. This may explain why women are more likely than men to develop dementia. The study also found that higher levels of p-tau217 predicted dementia in both white and black women, but were only associated with early memory problems in white participants. This discrepancy suggests that different factors may drive early cognitive decline in black women, requiring further investigation.

Experts have welcomed the findings but caution that more research is needed before the test can be used in clinical settings. Professor Tara Spires-Jones from the University of Edinburgh noted that the study highlights the importance of considering race, age, and HRT use when interpreting blood test results. 'Understanding how these factors influence the interpretation of this type of blood test is important for future clinical trials,' she said. However, she acknowledged that the research does not explain why HRT affects dementia risk or the effectiveness of the test.

Neurologists from the University of Oxford described the findings as 'impressive' but stressed that a positive test does not guarantee the development of dementia. 'Not everyone with high levels of the protein will develop dementia,' they said. This underscores the need for further validation and the importance of integrating the test with other diagnostic tools.

Michelle Dyson, Chief Executive Officer at Alzheimer's Society, highlighted the potential of blood tests to transform dementia diagnosis. 'Research we're funding aims to make a blood test routinely available on the NHS for symptomatic Alzheimer's disease within the next few years,' she said. The study's findings, she added, suggest a correlation between higher levels of the p-tau127 biomarker and an increased risk of dementia 25 years later. However, she emphasized that more research is needed to determine whether early identification of biomarkers can influence the progression of the disease.

For confidential advice on dementia, individuals can contact Alzheimer's Society's Dementia Support Line on 0333 150 3456. The society's symptoms checker is also available to help spot early signs of the condition. As research continues, the hope is that these advancements will lead to earlier interventions and improved outcomes for those at risk of dementia.